Food and Drug Administration (FDA) Commissioner Stephen Hahn in a recent speech said the agency will work toward permanent adoption of COVID-19 measures aimed at accelerating research and development, FierceBiotech reports.
“To the extent that innovations and adaptations we implemented during the pandemic crisis worked and would be appropriate to implement outside of a pandemic situation, we will incorporate them into standard FDA procedures,” he said. “And to the extent that we identified unnecessary barriers, we will remove them. This is one of my top priorities. Permanent change, where needed, will take place.”
To read the full report, click here.